cGVHD Clinical Trials

8 recruitingLast updated: May 21, 2026

There are 8 actively recruiting cgvhd clinical trials across 2 countries. Studies span Phase 2, Early Phase 1. Top locations include Charlotte, North Carolina, United States, Columbus, Ohio, United States, Atlanta, Georgia, United States. Updated daily from ClinicalTrials.gov.


cGVHD Trials at a Glance

8 actively recruiting trials for cgvhd are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Charlotte, Columbus, and Atlanta. Lead sponsors running cgvhd studies include Deciphera Pharmaceuticals, LLC, Grit Biotechnology, and BioPhoenix Co., Ltd..

Browse cgvhd trials by phase

About cGVHD Clinical Trials

Looking for clinical trials for cGVHD? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new cGVHD trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about cGVHD clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

Chronic Graft Versus Host DiseasecGVHD
University of Miami49 enrolled1 locationNCT06663722
Recruiting

Evaluation of Patients With Immune Function Abnormalities

Chronic Granulomatous Disease (CGD)X-Linked Severe Combined Immune Deficiency (XSCID)Leukocyte Adhesion Deficiency 1 (LAD)+1 more
National Institute of Allergy and Infectious Diseases (NIAID)3,500 enrolled1 locationNCT00128973
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)

cGVHD
Grit Biotechnology36 enrolled1 locationNCT07253259
Recruiting
Phase 2

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

Chronic Graft-Versus-Host Disease (cGVHD)
H. Lee Moffitt Cancer Center and Research Institute120 enrolled5 locationsNCT06660355
Recruiting

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

cGVHD
Incyte Corporation1,500 enrolled32 locationsNCT05919511
Recruiting
Phase 2

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

Chronic Graft-Versus-Host Disease (cGVHD)
Deciphera Pharmaceuticals, LLC48 enrolled26 locationsNCT06619561
Recruiting
Phase 2

BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation

Graft-Versus-Host DiseaseaGVHDcGVHD+1 more
BioPhoenix Co., Ltd.50 enrolled1 locationNCT07246031
Recruiting
Early Phase 1

Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2

cGVHD
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine18 enrolled1 locationNCT06920199